How big is Bolt Biotherapeutics, Inc.?

As of Jun 18, Bolt Biotherapeutics, Inc. has a market capitalization of 10.81 million, with net sales of 3.63 million and a net profit of -63.36 million over the latest four quarters. The company reported shareholder's funds of 57.20 million and total assets of 99.63 million as of Dec 24.

Market Cap: As of Jun 18, Bolt Biotherapeutics, Inc. has a market capitalization of 10.81 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Bolt Biotherapeutics, Inc. reported net sales of 3.63 million and a net profit of -63.36 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 57.20 million and total assets of 99.63 million.

What does Bolt Biotherapeutics, Inc. do?

Bolt Biotherapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $11 million as of March 2025. Key financial metrics include a market cap of $10.81 million, a negative P/E ratio, and a debt-to-equity ratio of -0.80.

Overview: <BR>Bolt Biotherapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 10.81 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.80 <BR>Return on Equity: -125.05% <BR>Price to Book: 0.23<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold Bolt Biotherapeutics, Inc.?

Is Bolt Biotherapeutics, Inc. overvalued or undervalued?

As of March 30, 2022, Bolt Biotherapeutics, Inc. is considered a risky investment due to its overvaluation and negative performance metrics, including a P/E ratio of -0.1998 and a significant one-year return of -57.46%, compared to the S&P 500's gain of 17.14%.

As of 30 March 2022, the valuation grade for Bolt Biotherapeutics, Inc. moved from does not qualify to risky, indicating increased scrutiny regarding its financial health. The company appears to be overvalued, particularly given its negative performance metrics. Key ratios such as the Price to Book Value at 0.26, EV to EBIT at 0.39, and EV to EBITDA at 0.40 highlight significant concerns about its valuation relative to its financial performance.<BR><BR>In comparison to its peers, Bolt Biotherapeutics has a P/E ratio of -0.1998, while Assembly Biosciences, Inc. and Fortress Biotech, Inc. show even more negative valuations at -9.3127 and -1.1589, respectively. This suggests that while Bolt is not alone in its struggles, it still faces substantial challenges. Over the past year, Bolt Biotherapeutics has underperformed significantly, with a return of -57.46% compared to the S&P 500's gain of 17.14%, reinforcing the notion that the stock is overvalued in its current state.

Is Bolt Biotherapeutics, Inc. technically bullish or bearish?

As of September 2, 2025, Bolt Biotherapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly with a year-to-date return of -50.57%.

As of 2 September 2025, the technical trend for Bolt Biotherapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI indicates a bullish monthly signal but no signal on the weekly. However, the moving averages are bearish on the daily, and Bollinger Bands show a mildly bearish trend on both weekly and monthly time frames. Additionally, the KST is mildly bullish weekly but bearish monthly, and the OBV is mildly bearish weekly with no trend monthly. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -50.57% versus the S&P 500's 12.22%, and a one-year return of -57.46% compared to the S&P 500's 17.14%.